Three patients had been suffering from benign halo nevus and focal vitiligo. They were treated with topical tacrolimus for 12 months. Remission was achieved in both the diseases. Pigmented moles of the halo nevi were unchanged and no harm was incurred to the patients. There was minimal self-limiting side effect from the tacrolimus.
| Published in | American Journal of Clinical and Experimental Medicine (Volume 2, Issue 5) |
| DOI | 10.11648/j.ajcem.20140205.13 |
| Page(s) | 103-105 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Benign Halo Nevus, Focal Vitiligo, Treatment, Topical Tacrolimus
| [1] | Stierman SC, Tierney EP, Shwayder TA. Halo congenital nevocellular nevi associated with extra lesional vitiligo. A case series with review of the literature. Pediatr Dermatol, 2009; 26: 414-424. |
| [2] | Frank SB and Cohen JH. The halo nevi. Archive Dermatol 1964; 89: 367-73. |
| [3] | Pearl E. Grimes, MD, Teresa Soriano, MD, and Mailene T. Dytoc MD, Ph D. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91. |
| [4] | William L. Epstein, MD; Richard Sagebeil, MD; Lynn Spitler, MD; Joseph Wybran, MD; William B. Reed, MD; M. Scot Blois. Halo nevi and melanoma. JAMA. 1973; 225(4): 373-377. |
| [5] | Copeman, P. W. M., Lewis, M. G., and Elliott, P. G. Immunological Associations of the Halo Naevus with Cutaneous Malignant Melanoma. Brit. J. Dermatol 1973; 88: 127-137. |
| [6] | Lawrence I. Tacrolimus (FK 506) experience in dermatology. Dermatol Ther 1998; 5: 74-84. |
APA Style
Delwar Hossain. (2014). Treating Benign Halo Nevus and Focal Vitiligo with Topical Tacrolimus: A Brief Report. American Journal of Clinical and Experimental Medicine, 2(5), 103-105. https://doi.org/10.11648/j.ajcem.20140205.13
ACS Style
Delwar Hossain. Treating Benign Halo Nevus and Focal Vitiligo with Topical Tacrolimus: A Brief Report. Am. J. Clin. Exp. Med. 2014, 2(5), 103-105. doi: 10.11648/j.ajcem.20140205.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajcem.20140205.13,
author = {Delwar Hossain},
title = {Treating Benign Halo Nevus and Focal Vitiligo with Topical Tacrolimus: A Brief Report},
journal = {American Journal of Clinical and Experimental Medicine},
volume = {2},
number = {5},
pages = {103-105},
doi = {10.11648/j.ajcem.20140205.13},
url = {https://doi.org/10.11648/j.ajcem.20140205.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20140205.13},
abstract = {Three patients had been suffering from benign halo nevus and focal vitiligo. They were treated with topical tacrolimus for 12 months. Remission was achieved in both the diseases. Pigmented moles of the halo nevi were unchanged and no harm was incurred to the patients. There was minimal self-limiting side effect from the tacrolimus.},
year = {2014}
}
TY - JOUR T1 - Treating Benign Halo Nevus and Focal Vitiligo with Topical Tacrolimus: A Brief Report AU - Delwar Hossain Y1 - 2014/10/10 PY - 2014 N1 - https://doi.org/10.11648/j.ajcem.20140205.13 DO - 10.11648/j.ajcem.20140205.13 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 103 EP - 105 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20140205.13 AB - Three patients had been suffering from benign halo nevus and focal vitiligo. They were treated with topical tacrolimus for 12 months. Remission was achieved in both the diseases. Pigmented moles of the halo nevi were unchanged and no harm was incurred to the patients. There was minimal self-limiting side effect from the tacrolimus. VL - 2 IS - 5 ER -
Information
Email: